GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report sent to investors on Monday,Benzinga reports. They currently have a $9.00 price target on the stock.

Other equities analysts also recently issued reports about the company. Alliance Global Partners lowered their target price on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research report on Tuesday, April 15th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, GeoVax Labs presently has a consensus rating of “Buy” and an average price target of $11.10.

GeoVax Labs Stock Performance

NASDAQ:GOVX opened at $1.32 on Monday. The firm has a market cap of $20.06 million, a price-to-earnings ratio of -0.36 and a beta of 3.45. The business’s fifty day moving average is $1.00 and its 200 day moving average is $1.57. GeoVax Labs has a 52-week low of $0.73 and a 52-week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.14. The company had revenue of $1.64 million for the quarter, compared to analysts’ expectations of $0.75 million. Equities analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the first quarter valued at approximately $703,000. Citadel Advisors LLC acquired a new stake in GeoVax Labs during the 4th quarter valued at $104,000. Geode Capital Management LLC grew its holdings in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Jane Street Group LLC acquired a new stake in GeoVax Labs during the 1st quarter valued at $27,000. Finally, Northern Trust Corp bought a new position in GeoVax Labs during the 4th quarter valued at $29,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.